The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Abstract
Cirrhosis and hepatocellular carcinoma occur as long-term complications of chronic hepatitis B virus (HBV) infection. Antiviral therapy is potentially a successful approach for the treatment of patients with HBV infection, which includes the nucleoside analog, lamivudine [(-)2′-deoxy-3′-thiacytidine, 3TC]. Although resistance to lamivudine therapy has been reported in several HBV-infected patients, the pattern of resistance-associated mutations in HBV has not been fully characterized. We report a DNA sequence database that includes a 500-base pair region of the HBV polymerase gene from 20 patients with clinical manifestations of lamivudine resistance. Analysis of the database reveals two patterns of amino acid substitutions in the tyrosine, methionine, aspartate, aspartate (YMDD) nucleotide-binding locus of the HBV polymerase. HBV DNA from the sera of patients in Group I exhibits a substitution of valine for methionine at residue 552, accompanied by a substitution of methionine for leucine at residue 528. Patients in Group II had only an isoleucine-for-methionine substitution at position 552. Reconstruction of these mutations in an HBV replication-competent plasmid was performed in a transient transfection cell assay to determine the function/relevance of these mutations to lamivudine resistance. Both Group I and Group II mutations resulted in a substantial decrease in sensitivity to lamivudine treatment (>10,000-fold shift in IC 50 over wild-type [wt] IC 50), strongly indicating that these mutations were involved in resistance to lamivudine. A hypothetical model of the HBV reverse transcriptase has been generated for further study of the role of these mutations in lamivudine resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Sells, M. A., Chen, M. L., & Acs, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.4.1005 · Cited by 1,117
Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115
Wong, D. K. H., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 984
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli
Galibert, F., Mandart, E., Fitoussi, F., Tiollais, P., & Charnay, P. (1979) · Nature · doi:10.1038/281646a0 · Cited by 981
Tiollais, P., & Buendia, M.-A. (1991) · Scientific American · doi:10.1038/scientificamerican0491-116 · Cited by 830
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,451
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Self-citationLong-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Histological outcome during long-term lamivudine therapy
Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W. L., Woessner, M., Stephenson, S. L., Gardner, S., Gray, D. F., & Schiff, E. R. (2003) · Gastroenterology · doi:10.1053/gast.2003.50013 · Cited by 726
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 689
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Self-citationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B
Jury, T. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00378-7 · Cited by 512
Beck, J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i1.48 · Cited by 494
Shouval, D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00152-1 · Cited by 470
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510300525 · Cited by 424
Hepatitis B: An important public health issue
Maddrey, W. C. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200007)61:3<362::aid-jmv14>3.0.co;2-i · Cited by 390
Yuen, M.-F., Sablon, E., Hui, C.-K., Yuan, H.-J., Decraemer, H., & Lai, C.-L. (2001) · Hepatology · doi:10.1053/jhep.2001.27563 · Cited by 386
van Bömmel, F., de Man, R. A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Hüppe, D., Stein, K., Trojan, J., et al. (2010) · Hepatology · doi:10.1002/hep.23246 · Cited by 330
Sarafianos, S. G., Das, K., Clark, A. D., Ding, J., Boyer, P. L., Hughes, S. H., & Arnold, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10027 · Cited by 309
Clinical Trial of Lamivudine in Children with Chronic Hepatitis B
Jonas, M. M., Kelley, D. A., Mizerski, J., Badia, I. B., Areias, J. A., Schwarz, K. B., Little, N. R., Greensmith, M. J., Gardner, S. D., Bell, M. S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012452 · Cited by 309
Lai, C., Rosmawati, M., Lao, J., Van Vlierberghe, H., Anderson, F. H., Thomas, N., & Dehertogh, D. (2002) · Gastroenterology · doi:10.1053/gast.2002.37058 · Cited by 302
van Bömmel, F., Zöllner, B., Sarrazin, C., Spengler, U., Hüppe, D., Möller, B., Feucht, H.-H., Wiedenmann, B., & Berg, T. (2006) · Hepatology · doi:10.1002/hep.21253 · Cited by 287
Sheldon, J., Camino, N., Rodés, B., Bartholomeusz, A., Kuiper, M., Tacke, F., Núñez, M., Mauss, S., Lutz, T., Klausen, G., et al. (2005) · Antiviral Therapy · doi:10.1177/135965350501000612 · Cited by 285
Hepatitis B virus genetic variability and evolution
Kay, A., & Zoulim, F. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.021 · Cited by 278
Clinical Pharmacokinetics of Lamivudine
Johnson, M. A., Moore, K. H. P., Yuen, G. J., Bye, A., & Pakes, G. E. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00004 · Cited by 275
Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G., & Arnold, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4771-4779.2001 · Cited by 274
Naturally Occurring Variants of Hepatitis B Virus
Günther, S., Fischer, L., Pult, I., Sterneck, M., & Will, H. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60298-5 · Cited by 255
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Strasfeld, L., & Chou, S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.001 · Cited by 254
Ghozy, S., Nam, N. H., Radwan, I., Karimzadeh, S., Tieu, T. M., Hashan, M. R., Abbas, A. S., Eid, P. S., Vuong, N. L., Khang, N. V., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2089 · Cited by 32
Metadata
- Authors
- Allen, M. I., Deslauriers, M., Andrews, W. C., Tipples, G. A., Walters, K.-A., Tyrrell, D. L., Brown, N., & Condreay, L. D.
- Venue
- Hepatology
- Published
- 1998-06
- Volume
- 27
- Issue
- 6
- Pages
- 1670-1677
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1985577568
- Cited by
- 793
- References
- 21
- FWCI
- 44.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.